$Impaired active relaxation during dynamic exercise in patients with heart failure with a preserved ejection fraction (HfpEF)$

Impaired active relaxation during dynamic exercise in patients with heart failure with a preserved ejection fraction (HfpEF)

Bibliographic Details
Main Authors:	Phan, T, Nallur-Shivu, G, Abozguia, K, Mahadevan, G, Ahmed, I, Anderson, S, Williams, L, Nassimizadeh, M, Clarke, K, Frenneaux, M
Format:	Journal article
Published:	2008

Similar Items

Tubulin expression and modification in heart failure with preserved ejection fraction (HFpEF)
by: Lisa Schulz, et al.
Published: (2022-09-01)

Proteomic and phosphoproteomic profiling in heart failure with preserved ejection fraction (HFpEF)
by: María Valero-Muñoz, et al.
Published: (2022-08-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): A Case Report
by: Amanda Halimi, et al.
Published: (2021-09-01)

Features of heart failure with preserved ejection fraction (HFpEF) in diabetic patients with resistant hypertension
by: M. A. Manukyan, et al.
Published: (2021-11-01)

Impact of readmissions on octogenarians with heart failure with preserved ejection fraction: PURSUIT‐HFpEF registry
by: Masami Nishino, et al.
Published: (2021-06-01)

Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency.
by: Phan, T, et al.
Published: (2009)

Focus on HFpEF in heart failure
by: Chunhui He, et al.
Published: (2022-05-01)

Predictors and Mortality for Worsening Left Ventricular Ejection Fraction in Patients With HFpEF
by: Liling Chen, et al.
Published: (2022-02-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 3 Devices Based Treatment and Commentary
by: Soneil Guptha , Eteri Tsetskhladze
Published: (2024-08-01)

Enhanced central sympathetic tone induces heart failure with preserved ejection fraction (HFpEF) in rats
by: Shyam S. Nandi, et al.
Published: (2023-12-01)

Stratified Treatment of Heart Failure with preserved Ejection Fraction: rationale and design of the STADIA‐HFpEF trial
by: Mariëlle Scheffer, et al.
Published: (2020-12-01)

Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and Recommendations
by: Dzhioeva O, et al.
Published: (2020-08-01)

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF
by: Shenghua Zhou, et al.
Published: (2025-03-01)

Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design
by: Prithwish Banerjee, et al.
Published: (2019-11-01)

The Oxygen Cascade According to HFpEF Likelihood
by: Jan Verwerft, MD, et al.
Published: (2024-07-01)

Carnitine is a friend in HFpEF and foe in HFrEF
by: Huiqing Wang, et al.
Published: (2024-10-01)

Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
by: Norman Mangner, et al.
Published: (2023-10-01)

Benefits of peritoneal ultrafiltration in HFpEF and HFrEF patients
by: Leonie Grossekettler, et al.
Published: (2020-05-01)

Arterial Stiffness Is an Important Predictor of Heart Failure with Preserved Ejection Fraction (HFpEF)—The Effects of Phosphate Retention
by: Yuji Mizuno, et al.
Published: (2024-05-01)

Accelerometer vs. other activity measures in heart failure with preserved ejection fraction: the VITALITY‐HFpEF trial
by: Javed Butler, et al.
Published: (2024-02-01)

Loeffler Endocarditis Causing Heart Failure with Preserved Ejection Fraction (HFpEF): Characteristic Images and Diagnostic Pathway
by: Silvia Lupu, et al.
Published: (2022-09-01)

Diabetes Is the Strongest Predictor of Limited Exercise Capacity in Chronic Heart Failure and Preserved Ejection Fraction (HFpEF)
by: Venera Berisha-Muharremi, et al.
Published: (2022-05-01)

Editorial: HFpEF and HFmrEF: Different Sides of the Same Coin?
by: Manuel Martínez-Sellés, et al.
Published: (2022-05-01)

Different determinants of exercise capacity in HFpEF compared to HFrEF
by: Arlind Batalli, et al.
Published: (2017-04-01)

Prognostic significance of dipstick proteinuria in heart failure with preserved ejection fraction: insight from the PURSUIT-HFpEF registry
by: Tetsuhisa Kitamura, et al.
Published: (2021-09-01)

Application Value of Systemic Inflammatory Indexes in the Clinical Evaluation of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)
by: Ruxin Wang, et al.
Published: (2022-10-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 1 Review of Experience and Evidence in PARAGON-HF with Commentary
by: Soneil Guptha; Eteri Tsetskhladze
Published: (2023-07-01)

Predictive potential of macrophage migration inhibitory factor (MIF) in patients with heart failure with preserved ejection fraction (HFpEF)
by: Peter Luedike, et al.
Published: (2018-05-01)

Epicardial adipose tissue and exercise intolerance in HFpEF
by: Michelle Lobeek, et al.
Published: (2024-10-01)

HFpEF as systemic disease, insight from a diagnostic prediction model reminiscent of systemic inflammation and organ interaction in HFpEF patients
by: Rong Zhou, et al.
Published: (2024-03-01)

Characteristics, prognosis, and treatment response in HFpEF patients with high vs. normal ejection fraction
by: Jun Gu, et al.
Published: (2022-09-01)

Hemodynamic force assessment by cardiovascular magnetic resonance in HFpEF: A case-control substudy from the HFpEF stress trialResearch in context
by: Sören J. Backhaus, et al.
Published: (2022-12-01)

Prevalence of Prediabetes and Newly diagnosed Diabetes in Patients with HFpEF and HFrEF
by: Ahmad ELSharawy, et al.
Published: (2024-01-01)

Heart Failure with Preserved Ejection Fraction (HFpEF): Part 2 Review of Experience and Evidence with SGLT-2 Inhibitors and Commentary
by: Soneil Guptha, Eteri Tsetskhladze
Published: (2023-06-01)

Incidence of heart failure with preserved ejection fraction (HFpEF) in COPD patients during acute exacerbation in Ain Shams University Hospitals
by: Hossam H Sayed, et al.
Published: (2024-01-01)

Executive Summary from the 2023 Charleston HFpEF Conference
by: Sheldon E Litwin, et al.
Published: (2024-06-01)

Association of Plasma Myeloperoxidase with Inflammation and Diabetic status in HFpEF
by: Sibille Lejeune, et al.
Published: (2023-02-01)

Hemodynamic force analysis is not ready for clinical trials on HFpEF
by: Per M. Arvidsson, et al.
Published: (2022-03-01)

Leukocyte count and the risk of adverse outcomes in patients with HFpEF
by: Zhaowei Zhu, et al.
Published: (2021-07-01)

Phenotypic Trajectories From Acute to Stable Phase in Heart Failure With Preserved Ejection Fraction: Insights From the PURSUIT‐HFpEF Study
by: Yuki Matsuoka, et al.
Published: (2025-02-01)